2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

The Dow Jones Industrial Average fell 382.15 points, or 0.86%, to 43,910.98, the S&P 500 lost 17.36 points, or 0.29%, to ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

As an aside, in the tech space, see What’s Happening With Snap Stock? Although the recent Amgen update didn’t bode well with ...

Shares of pharmaceutical giant Amgen (AMGN) are attempting to bounce back after suffering a steep drop of 7.1% yesterday.

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm ...

Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a ...

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...